Caspofungin Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The market is segmented by Indication (Candidiasis, Thrush and Others), Distribution Channel and Geography

Market Snapshot

Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 1.8 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The caspofungin market studied was anticipated to grow with a CAGR of 5.6% during the forecast period. The major factors attributing to the growth of the market are rise in candidiasis and candidemia cases with decreased immunity and unhygienic habits. As per the study report published by the National Center for Biotechnology in 2019, Candidemia is the most common fungal bloodstream infection and remains the fourth most common all-type bloodstream infection seen in the intensive care unit setting. Also, a rise in smoking and alcohol consumption among men is expected to result in a greater number of new fungal infections necessitating an efficient treatment. Thus, the above-mentioned factors are expected to propel the global caspofungin market throughout the forecast period.

Scope of the Report

Caspofungin is an echinocandin class of antifungal drugs. The drug competitively inhibits 1,3-β glucan synthase, an enzyme that is essential for the synthesis of β-glucan in the fungal cell wall. Thus, by disrupting the cell wall integrity the drug exhibits its antifungal activity. It is available as an intravenous infusion form and administered once a day to treat against Candida and Aspergillus species infection.

Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Candidiasis Segment is Expected to Hold the Major Market Share in the Caspofungin Market

The candidiasis segment is expected to dominate the industry over the forecast period. The lucrative growth of the segment can be attributed to a rise in the prevalence of esophageal candidiasis among men and vaginal yeast infections among women. Also, due to approval of caspofungin as the first line of treatment of patients with invasive candidiasis and who are resistant to other antifungal agents is expected to boost the growth of the market. As per the Infectious Diseases Society of America report, published in February 2020, Candida Auris is multidrug-resistant and emerged as a global health threat. Serious outbreaks by this C. Auris can be treated with caspofungin. Thus, increased adoption of caspofungin to treat various types of Candidiasis such as intra-abdominal abscesses, peritonitis, and pleural space infections is likely the growth of the segment over the forecast period.

Global geriatric Diabetes IDF.png

North America Dominates the Market and Expected to do Same in the Forecast Period.

North America is expected to dominate the global caspofungin market throughout the forecast period. This dominance is mainly owing to rising incidences of vaginal, vulvovaginal and fungemia candidiasis due to changes in lifestyles and a rise in stress. Increased incidences of Candidemia and invasive aspergillosis due to a huge population of geriatrics in the United States. As per the Centers for Disease Control and Prevention (CDC) report published in 2019, Candida is the 4th most common cause of bloodstream infection among the people aged 60 or above. Also, a higher prescription of antibiotics, uncontrolled diabetes in the region fuels the market. The presence of key players and early product launches in the region are expected to contribute its outstanding share in the growth of global market revenue over the forecast period.

Mordor Intelligence

Competitive Landscape

The global caspofungin market is moderately competitive and consists of several major players. Some prominent players in the market are implementing various strategies such as launching new products and making acquisitions to consolidate their market positions across the globe. For instance, In September 2017, Fresenius Kabi introduced the First and only room-temperature caspofungin formulation in the U.S. The company launched the first-to-market generic to Merck’s CANCIDAS used in the treatment of candidemia and other fungal infections. Such innovative product launches are expected to have a positive impact on the growth of the market during the forecast period. Some of the companies which are currently dominating the market are Merck & Co., Inc., Fresenius SE & Co. KGaA (Fresenius Kabi), Juno Pharmaceuticals (MDA Inc.), Athenex, Inc., and Cipla Inc.

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Global Prevalence of Chronic Disorders like Diabetes and Cancer

      2. 4.2.2 Rising Usage of Caspofungin over other Echinocandins

    3. 4.3 Market Restraints

      1. 4.3.1 Highly Expensive Patented Products

      2. 4.3.2 Severe Complications like Stevens-Johnson Syndrome (SJS) Associated with the Medication

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 Indication

      1. 5.1.1 Candidiasis

      2. 5.1.2 Thrush

      3. 5.1.3 Others

    2. 5.2 Distribution Channel

      1. 5.2.1 Hospital Pharmacies

      2. 5.2.2 Retail Pharmacies

      3. 5.2.3 Online Pharmacies

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Fresenius SE & Co. KGaA (Fresenius Kabi)

      2. 6.1.2 Alvogen Inc.

      3. 6.1.3 Juno Pharmaceuticals (MDA Inc.)

      4. 6.1.4 Cipla Inc.

      5. 6.1.5 Merck & Co., Inc.

      6. 6.1.6 Athenex, Inc.

      7. 6.1.7 Sanofi S.A.

      8. 6.1.8 Sundent Pharmaceutical Co. Ltd.

      9. 6.1.9 Gland Pharma Limited

      10. 6.1.10 Sun Pharmaceutical Industries Ltd.

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Caspofungin Market market is studied from 2018 - 2026.

The Caspofungin Market is growing at a CAGR of 1.8% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Athenex, Inc., Cipla Inc., Fresenius SE & Co. KGaA (Fresenius Kabi), Juno Pharmaceuticals (MDA Inc.), Merck & Co., Inc. are the major companies operating in Caspofungin Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!